148 related articles for article (PubMed ID: 16527213)
1. [Dominant negative activity of mutated p53 proteins].
Dridi W; Krabchi K; Gadji M; Lavoie J; Bronsard M; Fetni R; Drouin R
Med Sci (Paris); 2006 Mar; 22(3):301-7. PubMed ID: 16527213
[TBL] [Abstract][Full Text] [Related]
2. In vitro analysis of the dominant negative effect of p53 mutants.
Chène P
J Mol Biol; 1998 Aug; 281(2):205-9. PubMed ID: 9698540
[TBL] [Abstract][Full Text] [Related]
3. Mutant p53 exerts a dominant negative effect by preventing wild-type p53 from binding to the promoter of its target genes.
Willis A; Jung EJ; Wakefield T; Chen X
Oncogene; 2004 Mar; 23(13):2330-8. PubMed ID: 14743206
[TBL] [Abstract][Full Text] [Related]
4. Dominance of wild-type p53-mediated transcriptional activation in breast epithelial cells.
Davis P; Bazar K; Huper G; Lozano G; Marks J; Iglehart JD
Oncogene; 1996 Sep; 13(6):1315-22. PubMed ID: 8808706
[TBL] [Abstract][Full Text] [Related]
5. The p53 tumor suppressor gene and gene product.
Levine AJ
Princess Takamatsu Symp; 1989; 20():221-30. PubMed ID: 2488233
[TBL] [Abstract][Full Text] [Related]
6. Targeted point mutations of p53 lead to dominant-negative inhibition of wild-type p53 function.
de Vries A; Flores ER; Miranda B; Hsieh HM; van Oostrom CT; Sage J; Jacks T
Proc Natl Acad Sci U S A; 2002 Mar; 99(5):2948-53. PubMed ID: 11867759
[TBL] [Abstract][Full Text] [Related]
7. Mutant p53: gain-of-function oncoproteins and wild-type p53 inactivators.
Roemer K
Biol Chem; 1999; 380(7-8):879-87. PubMed ID: 10494837
[TBL] [Abstract][Full Text] [Related]
8. Tumor suppressor genes.
Levine AJ
Bioessays; 1990 Feb; 12(2):60-6. PubMed ID: 2140509
[TBL] [Abstract][Full Text] [Related]
9. Mutant p53 proteins behave in a dominant, negative fashion in vivo.
Hachiya M; Chumakov A; Miller CW; Akashi M; Said J; Koeffler HP
Anticancer Res; 1994; 14(5A):1853-9. PubMed ID: 7847818
[TBL] [Abstract][Full Text] [Related]
10. p53 mutants without a functional tetramerisation domain are not oncogenic.
Chène P; Bechter E
J Mol Biol; 1999 Mar; 286(5):1269-74. PubMed ID: 10064694
[TBL] [Abstract][Full Text] [Related]
11. [Dominant-negative inactivation of p53: the effect of the proportion between trans-dominant inhibitor and its target].
Morgunkova AA; Almazov VP; Strunina SM; Kopnin BP; Chumakov PM
Mol Biol (Mosk); 2003; 37(1):112-20. PubMed ID: 12624953
[TBL] [Abstract][Full Text] [Related]
12. Transactivational and DNA binding abilities of endogenous p53 in p53 mutant cell lines.
Park DJ; Nakamura H; Chumakov AM; Said JW; Miller CW; Chen DL; Koeffler HP
Oncogene; 1994 Jul; 9(7):1899-906. PubMed ID: 8208536
[TBL] [Abstract][Full Text] [Related]
13. Structural basis of restoring sequence-specific DNA binding and transactivation to mutant p53 by suppressor mutations.
Suad O; Rozenberg H; Brosh R; Diskin-Posner Y; Kessler N; Shimon LJ; Frolow F; Liran A; Rotter V; Shakked Z
J Mol Biol; 2009 Jan; 385(1):249-65. PubMed ID: 18996393
[TBL] [Abstract][Full Text] [Related]
14. Mutant p53: an oncogenic transcription factor.
Strano S; Dell'Orso S; Di Agostino S; Fontemaggi G; Sacchi A; Blandino G
Oncogene; 2007 Apr; 26(15):2212-9. PubMed ID: 17401430
[TBL] [Abstract][Full Text] [Related]
15. p53 from complexity to simplicity: mutant p53 stabilization, gain-of-function, and dominant-negative effect.
Blagosklonny MV
FASEB J; 2000 Oct; 14(13):1901-7. PubMed ID: 11023974
[TBL] [Abstract][Full Text] [Related]
16. Several mutant p53 proteins detected in cancer-prone families with Li-Fraumeni syndrome exhibit transdominant effects on the biochemical properties of the wild-type p53.
Srivastava S; Wang S; Tong YA; Pirollo K; Chang EH
Oncogene; 1993 Sep; 8(9):2449-56. PubMed ID: 8361758
[TBL] [Abstract][Full Text] [Related]
17. 9-Hydroxyellipticine alters the conformation and DNA binding characteristics of mutated p53 protein.
Sugikawa E; Tsunoda S; Nakanishi N; Ohashi M
Anticancer Res; 2001; 21(4A):2671-5. PubMed ID: 11724337
[TBL] [Abstract][Full Text] [Related]
18. Gain-of-function mutations in the tumor suppressor gene p53.
van Oijen MG; Slootweg PJ
Clin Cancer Res; 2000 Jun; 6(6):2138-45. PubMed ID: 10873062
[TBL] [Abstract][Full Text] [Related]
19. Restoring wild-type conformation and DNA-binding activity of mutant p53 is insufficient for restoration of transcriptional activity.
Brazda V; Muller P; Brozkova K; Vojtesek B
Biochem Biophys Res Commun; 2006 Dec; 351(2):499-506. PubMed ID: 17070499
[TBL] [Abstract][Full Text] [Related]
20. Tumour associated mutants of p53 can inhibit transcriptional activity of p53 without heterooligomerization.
Jõers A; Kristjuhan A; Kadaja L; Maimets T
Oncogene; 1998 Nov; 17(18):2351-8. PubMed ID: 9811466
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
